Meissa's Positive Interim Clinical Data for Its Intranasal Live Attenuated RSV Vaccine for Infants

Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines

Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

The Scientist: Nasal Vaccines Are Commercially High Risk, Perhaps High Reward

Bloomberg BusinessWeek: Why Nasal Sprays Are Poised to Be the Next Weapon for Fighting Covid

The Washington Post: The Next Leap in Coronavirus Vaccine Development Could Be a Nasal Spray

News Channel Nebraska: Hastings Doctor Leading ‘History-Making’ RSV Vaccine Trial

Meissa Appoints Drs. Dan H. Barouch and Mark J. Mulligan to Scientific Advisory Board

FierceBiotech: Meissa's Early Clinical Data on COVID-19 Vaccine Supports Transmission Blocking Role

Yahoo! News: A Nasal COVID-19 Vaccine Could Be the Solution to Ending the Pandemic, Experts Say

Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID

JAMA: Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines

BioPharm International: Meissa’s Intranasal COVID-19 Vaccine Yields Promising Preclinical Data

Science: Scent of a Vaccine

National Geographic: A Spritz Instead of a Jab? Future COVID-19 Vaccines May Go up Your Nose.

Reuters: Intranasal Vaccine Aims to Block Virus at Point of Entry

BioSpace: Meissa's Intranasal COVID-19 Vaccine Shows Promise in Non-Human Primates

MedCity News: Meissa Vaccines’ Leg up in the Covid-19 Vaccines Chase Goes through the Nose

Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose

Big4Bio Podcast: How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine

Big4Bio: Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV

Big4Bio: Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges

Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

BioPharm International: Modernizing Intranasal Live Attenuated Vaccines